Patent Issued in Jordan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)

Jaguar Health, Inc. has announced that Jordan's Industrial Property Protection Directorate has issued a new patent to its subsidiary Napo Pharmaceuticals for methods treating short bowel syndrome (SBS) and other related conditions. This patent enhances the protection of crofelemer, Jaguar's plant-based prescription drug.

Jaguar currently holds approximately 230 patents issued and pending. The company is also supporting proof-of-concept studies of crofelemer for SBS and microvillus inclusion disease (MVID) in various regions, with results expected by the end of 2024 and throughout 2025.

Some SBS patients face intestinal failure, requiring intensive parenteral nutrition (PN). MVID is a severe condition characterized by infantile diarrhea and requires significant nutritional and fluid management due to the lack of approved drug treatments.

Jaguar and Napo prioritize intellectual property protection to bolster their portfolio. Crofelemer remains the sole oral plant-based prescription medicine approved by the FDA under its Botanical Guidance, providing an exclusivity advantage.